KalVista Pharmaceuticals, Inc. (KALV) — Financial statements
Income statement, balance sheet, and cash flow for KalVista Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 74 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 6 | 0.00↓100.0% | 86 | 0.00 | 0.00 | |
| Gross Profit | 68 | 0.00↑100.0% | -86 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 56↓22.4% | 72↓16.8% | 86↑7.3% | 80↑14.4% | 70 | |
| General & Administrative Expenses | 0.00↓100.0% | 116↑114.2% | 54↑77.4% | 31↑15.7% | 26 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 184↑58.0% | 116↑114.2% | 54↑77.4% | 31↑15.7% | 26 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -86 | 0.00 | 0.00 | |
| Operating Expenses | 239↑27.3% | 188↑246.4% | 54↓51.0% | 111↑14.8% | 97 | |
| Total Costs & Expenses | 245↑30.6% | 188↑33.9% | 140↑26.7% | 111↑14.8% | 97 | |
| Operating Results | ||||||
| Operating Income | -172↑8.6% | -188↓33.9% | -140↓26.7% | -111↓14.8% | -97 | |
| Depreciation & Amortization | 1↑54.5% | 0.94↑15.3% | 0.82↑13.6% | 0.72↑27.3% | 0.56 | |
| EBITDA | -170↑1.7% | -173↓29.1% | -134↓42.3% | -94↓16.9% | -81 | |
| EBIT | -172↑1.4% | -174↓29.0% | -135↓42.1% | -95↓16.9% | -81 | |
| Interest & Other Income | ||||||
| Net Interest Income | -11↓1739.8% | 0.65 | 0.00↓100.0% | 2↑104.8% | 1 | |
| Interest Income | 9↑34.9% | 6 | 0.00↓100.0% | 2↑104.8% | 1 | |
| Interest Expense | 19↑234.4% | 6 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -14↓156.6% | -5↑66.1% | -16↓3.1% | -15 | |
| Other Income / Expenses | 0.42↓94.7% | 8↑48.5% | 5↓70.2% | 18↑25.9% | 14 | |
| Income Before Tax | -171↑4.8% | -180↓33.3% | -135↓45.4% | -93↓12.8% | -82 | |
| Income Tax Expense | -7↓310.3% | 3↑140.1% | -8 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -164↑10.4% | -183↓44.9% | -127↓36.3% | -93↓12.8% | -82 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -164↑10.4% | -183↓44.9% | -127↓36.3% | -93↓12.8% | -82 | |
| Bottom-Line Net Income | -164↑10.4% | -183↓44.9% | -127↓36.3% | -93↓12.8% | -82 | |
| EPS (Basic) | -3.23↑12.5% | -3.69↓7.3% | -3.44↓3.3% | -3.33↑0.9% | -3.36 | |
| EPS (Diluted) | -3.23↑12.5% | -3.69↓7.3% | -3.44↓3.3% | -3.33↑0.9% | -3.36 | |
| Weighted Average Shares | 51↑2.5% | 50↑35.0% | 37↑31.9% | 28↑14.0% | 24 | |
| Weighted Average Diluted Shares | 51↑2.5% | 50↑35.0% | 37↑31.9% | 28↑14.0% | 24 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.